Platelet-derived growth factor
receptor-[alpha][alpha] and PDGF-AA were increased in higher grade tumors when compared with those of grades 1 and 2.
Vasodilators Nitric oxide (EDRF) Hyperpolarizing factors) Prostacyclin Vasoconstrictors ET Angiotensin II Thromboxane A2 Cellular adhesion molecules VCAM-1 Intercellular cell adhesion molecule E-selectin Growth factors Vascular endothelial growth factor Platelet-derived growth factor
Transforming growth factor Heparin-binding epidermal growth factor M-CSF Coagulants/fibrinolytics von Willebrand factor Tissue type plasminogen activator Plasminogen activator inhibitor Chemokines Monocyte chemotactic protein ?
Lenvatinib, discovered and developed by Eisai, is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor receptors (FGFR), the platelet-derived growth factor
(PDGF) receptor PDGFR?
Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in [Alpha]-granules, platelet factor 4, [Beta]-thromboglobulin, and platelet-derived growth factor
01% contains becaplermin, a human platelet-derived growth factor
that is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply.
BIBF 1120 is a novel triple angiokinase inhibitor that simultaneously inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor
receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs)(1) - all of which are crucially involved in the formation of blood vessels.
In a retrospective cohort study of 25,098 patients, approximately 10% were treated with becaplermin (Regranex), a topical recombinant human platelet-derived growth factor
The product is comprised of recombinant human platelet-derived growth factor
and a tri-calcium phosphate and collagen carrier (rhPDGF-BB/-TCP/collagen).
All Augment branded products are based upon recombinant human platelet-derived growth factor
(rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration.
BIBF 1120 is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis, or the formation of blood vessels: fibroblast growth factor receptor (FGFR), platelet-derived growth factor
receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR).
But among 40 GISTs that expressed the normal version of KIT receptor tyrosine kinase, 14 had mutations in the related kinase, platelet-derived growth factor
receptor-[alpha]; none of 36 KIT-mutant GISTs had that mutation (Science 299:708-10, 2003).
GEM 21S is composed of the tissue growth factor, recombinant human Platelet-Derived Growth Factor
(rhPDGF-BB), and a synthetic bone matrix, Beta-tricalcium phosphate (-TCP).
01% Becaplermin) is a recombinant human platelet-derived growth factor
(rhPDGF) and was the first biotechnology product approved for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply.